Diego Ripamonti - Malattie Infettive - Bergamo Simposio HOT TOPICS Hot topics in HIV 2015.

Slides:

Advertisements

Similar presentations

Antiretroviral Therapy: An HIV Prevention Strategy? Wafaa El-Sadr, MD, MPH Columbia University Harlem Hospital New York.

Advertisements

Tuberculosis incidence and risk factors among adult patients receiving HAART in Senegal: a 7-year cohort study Assane DIOUF et al. IRD/UMR 145 CRCF, CHNU.

Recommendations of BU/HIV expert panel influenced by results from Akonolinga All BU patients should be offered quality provider-initiated HIV testing and.

Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.

PEPFAR Hepatitis B co-infection and Response to Antiretroviral Therapy among HIV-infected Patients in Tanzania Oral abstract # MOAB0101 C. Hawkins, B.

1 The START Trial: On the Shoulders of SMART 5 years after SMART INSIGHT Satellite Session WAC, Washington DC, July 2012.

Slide 1 of 11 From CB Hicks, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Charles B. Hicks, MD Professor of Medicine Duke University Medical Center.

Most deaths among children enrolled in two program settings in Cambodia occur within the first 6 months after enrolment. Early mortality rates were more.

ICS in COPD – A Risk Factor for CAP? Rate of pneumonia in ICS Studies

Immune Reconstitution Inflammatory Syndrome (IRIS)

Cost-effectiveness of different starting criteria of antiretroviral therapy in Mexico. Caro Y., Colchero A., Valencia A., Bautista-Arredondo S., Sierra.

HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.

START study: UK-CAB July2015 Community feedback: START study Simon Collins HIV i-Base

IAS–USA When to Start Antiretroviral Therapy Constance A. Benson, MD Professor of Medicine University of California San Diego FINAL: Presented.

Slide 1 of 11 From DA Wohl, MD, at New York, NY: May 03, 2012, IAS-USA. IAS–USA David Alain Wohl, MD Associate Professor of Medicine The University of.

The Immunologic Efficacy of Antiretroviral Therapy among HIV-infected Patients in North America and Africa Elvin Geng* 1, Eric Vittinghoff 1, Jean Nachega.

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.

When to Start. Data Presentation DHHS and IAS-USA: Recommendations for Initiation of ART in Naïve Patients Available at:

STRATEGIE THERAPEUTIQUE JL Meynard Hôpital Saint-Antoine PARIS.

HIV and serious non-AIDS conditions Five Years after the SMART Study, a Paradigm Shifting Trial INSIGHT Symposium XIX International AIDS Conference Washington.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

HIV i-Base: SMART Study & CROI Feedback UK-CAB - Feb 2006 UK-CAB 24 February 2006 CROI Feedback: SMART Study Simon Collins.

Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.

The Timing of ART initiation in TB HIV co-infected patients: Impact on IRIS severity 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention 20.

Impact of early surgery vs conventional treatment for infective endocarditis on mortality and embolic events: data from EASE trial Prospective RCT ( );

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500.

TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)

ART: When to Start? – Case Discussion Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell.

Supported by: NIAID/NHLBI R24 AI067039, NIAID R21 AI Viremia copy-years: A measure of cumulative HIV burden among patients initiating antiretroviral.

Predictors of ART-associated TB in a prospective study: Results of the Kericho IRIS Study The Rainbow of IRIS in HIV Infection July 26, 2012 Fredrick.

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

Switch to RAL-containing regimen  Canadian Study  CHEER  Montreal Study  EASIER  SWITCHMRK  SPIRAL  Switch ER.

Can early antiretroviral therapy fully restore health? Workshop on Pathogeneses and Management of Long-Term Complications of ART IAS Conference, Rome July.

Grinsztejn B, et al, Lancet Infect Dis, March 4 th 2014 PRIMARY COMBINED M&M OUTCOME FIRST AIDS DEFINING EVENT FIRST TB EVENT DEATH.

Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.

A Call to Action Children – The missing face of AIDS.

Weekly Alendronate Safe and Effective at Increasing Bone Mineral Density in HIV-Infected Persons on Antiretroviral Therapy Slideset on: McComsey GA, Kendall.

Effect of ART on malaria parasitaemia and clinical episodes in adults in rural Uganda: A population-based cohort study Billy N. Mayanja 1, Kathy Baisley.

Cost-effectiveness of initiating and monitoring HAART based on WHO versus US DHHS guidelines in the developing world Peter Mazonson, MD, MBA Arthi Vijayaraghavan,

Hot Topics in Infectious Diseases Giuseppe Nunnari.

Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.

Nuovi paradigmi della HAART Antonella Castagna IRCCS San Raffaele Nuove associazioni terapeutiche in HIV, tra efficacia e sostenibilita Catania, 9 novembre.

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection The INSIGHT START Study Group Ben Andres Oct 15, 2015.

Efavirenz Use Not Associated With Depressive Episodes, According to Analysis of Randomized Clinical Trial Outcomes Slideset on: Journot V, Chene G, De.

Dr. William P. Howlett Matthew P. Rubach, MD Dr. Neema W. Minja Department of Internal Medicine, KCMC KCMC/Duke Collaboration HIV in Tanzania: Current.

Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:

Long-term clinical and viro-immunologic outcomes of post-treatment controllers (PTCs) in the ANRS-VISCONTI study Laurent HOCQUELOUX, MD Orléans’ Regional.

Henry Masur, MD Bethesda, Maryland

Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.

First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.

Who Benefited Most From Immediate Treatment in START A Subgroup Analysis JM Molina, B Grund, F Gordin, I Williams, M Schechter, M Losso, M Law, E Ekong,

Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.

Daouda Diouf Executive Director Enda Santé Dakar, Senegal

Novel Antiretroviral Studies and Strategies

Towards ending the AIDS Epidemic: Progress and Evidence

Incidence of tuberculosis in the first year of antiretroviral treatment in West-African HIV-infected adults B. Tchakounte Youngui1, P. Coffie2, E. Messou3,

ART was initiated when indicated by WHO and national guidelines

Acceptability of early HIV treatment among South Africa women N Garrett, E Norman, V Asari, N Naicker, N Majola, K Leask, Q Abdool Karim and SS Abdool.

Dolutegravir plus Rilpivirine as Maintenance Dual Therapy SWORD-1 and SWORD- 2: Design

CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

Presented by: Daniel Poe Sana Safeer March 24, 2016

Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load by Steven G. Deeks, Christina.

Diabetes Journal Club March 17, 2011

When to START During an OI

Switch to RAL-containing regimen

Volume 373, Issue 9672, Pages (April 2009)

Switch to DTG-containing regimen

Presentation transcript:

Diego Ripamonti - Malattie Infettive - Bergamo Simposio HOT TOPICS Hot topics in HIV 2015

Disclosures Diego Ripamonti received advisory fees, speaker fees, travel and education from: - Abbott - BMS - ViiV - Janssen - Merk - Gilead 2

- START - Temprano UNAIDS OMS Universal treatment Convergence of International Guidelines CD4/CD8 ratio following HIV therapy new biomarkers of HIV disease Burden of non-AIDS morbidity HOT Topics – SIMIT 2015

INSIGHT START Study Group. NEJM 2015

START: Immediate vs Deferred Therapy for Asymptomatic, ART-Naive pts Immediate ART ART initiated immediately following randomization (n = 2326) Deferred ART Deferred until CD4+ cell count ≤ 350 cells/mm 3, AIDS, or event requiring ART (n = 2359) HIV-positive, ART-naive adults with CD4+ cell count > 500 cells/mm 3 (N = 4685) Study closed by DSMB (after interim analysis) HOT Topics – SIMIT 2015 INSIGHT START Study Group. NEJM 2015

HOT Topics – SIMIT 2015 INSIGHT START Study Group. NEJM 2015

Serious AIDS-related or serious non AIDS-related events (including death) Composite primary end-point HOT Topics – SIMIT 2015 INSIGHT START Study Group. NEJM % events in pts with CD4 > 500 cells

HOT Topics – SIMIT 2015 The TEMPRANO ANRS Study Group. NEJM 2015

HOT Topics – SIMIT 2015 The TEMPRANO ANRS Study Group. NEJM 2015 In Ivory Coast Total pts: arms: - Def ART* - Def+ IPT - Early ART - Early + IPT * by WHO criteria 42% of clinical events are TB

HOT Topics – SIMIT 2015

UNAIDS: Treatment Targets HIV Positive People DiagnosedOn ARTViral Suppression 36.9 million 33.2 million 29.5 million 26.9 million Target 1: 90% of HIV+ people diagnosed Target 2: 90% of diagnosed people on ART Target 3: 90% of people on ART with HIV-1 RNA suppression 90% 81% 73% People (%) HOT Topics – SIMIT 2015

March 2015: UNAIDS announces that the goal of 15 million people on life-saving HIV treatment by 2015 has been met nine months ahead of schedule

HOT Topics – SIMIT 2015

Però.…

HOT Topics – SIMIT 2015 Mussini C et al. Lancet HIV 2015;2:e98-e106

HOT Topics – SIMIT 2015 Mussini C et al. Lancet HIV 2015;2:e98-e106 ICONA cohort 3236 pts with CD4/CD8 < 0.8 (median 0.39) From on HAART Probability of normalization by 5 year: 29.4% Predictors: high baseline CD4, higher CD4/CD8 and CMV serology negative CD4/CD8 ratio < 0.30  higher risk of non-AIDS defining events or death

HOT Topics – SIMIT 2015 Serrano-Villar S, Deeks SG. Lancet HIV 2015;2:e76-7 CD4

HOT Topics – SIMIT 2015 Seng R et al. AIDS 2015; 29:

HOT Topics – SIMIT 2015 HAARTN. ptsF-up since infection F-up since therapy CD4/CD8 > 1 Early yrs4.8 yrs36.1% Deferred, continuous yrs3.0 yrs39.8% Cumulative viremiaRisk of achieving CD4/CD8 > 1 > 66rd percentile26.6% < 33rd percentile43.3% After controlling for: - baseline CD4/CD8 ratio - HAART duration - sex - age OR: 0.34 (95%CI ), p=0.003 ANRS Primo Cohort Seng R et al. AIDS 2015; 29:

2015: Treat early and all 1996: Hit early and hard HOT Topics – SIMIT 2015

FINE

HOT Topics – SIMIT 2015 Only few patients normalise CD4/CD8 ratio, even after a long time on suppressive antiretorivral therapy. The incidence rate of non-AIDS defining events when the CD4/CD8 ratio was less than 0.30 was more than two-time higher than that observed when the CD4/CD8 ratio was more than CD4/CD8 ratio may be a simple and inexpensive instrument to interprete the state of immune activation and risk of non-AIDS-defining events, even in patients with high CD4 count Mussini C et al. Lancet HIV 2015;2:e98-e106 Interpretation

HOT Topics – SIMIT 2015 Secondary end-points INSIGHT START Study Group. NEJM 2015

Increased risk of serious non-AIDS-related events and a low CD4/CD8 ratio. Case-control study: 109 cases, 298 controls - non-AIDS morbidity - non-AIDS mortality Serrano–Villar S et al. PLoS One ; 1: e85798.

HOT Topics – SIMIT 2015

INSIGHT START Study Group. NEJM 2015